FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313892883> ?p ?o ?g. }

• W4313892883 abstract "PURPOSE Programmed cell death protein-1 (PD-1) receptor and ligand interactions are the target of immunotherapies for more than 20 cancer types. Biomarkers that predict response to immunotherapy are microsatellite instability, tumor mutational burden, and programmed death ligand-1 (PD-L1) immunohistochemistry. Structural variations (SVs) in PD-L1 ( CD274) and PD-L2 ( PDCD1LG2) have been observed in cancer, but the comprehensive landscape is unknown. Here, we describe the genomic landscape of PD-L1 and PD-L2 SVs, their potential impact on the tumor microenvironment, and evidence that patients with these alterations can benefit from immunotherapy. METHODS We analyzed sequencing data from cancer cases with PD-L1 and PD-L2 SVs across 22 publications and four data sets, including Foundation Medicine Inc, The Cancer Genome Atlas, International Cancer Genome Consortium, and the Oncology Research Information Exchange Network. We leveraged RNA sequencing to evaluate immune signatures. We curated literature reporting clinical outcomes of patients harboring PD-L1 or PD-L2 SVs. RESULTS Using data sets encompassing 300,000 tumors, we curated 486 cases with SVs in PD-L1 and PD-L2 and observed consistent breakpoint patterns, or hotspots. Leveraging The Cancer Genome Atlas, we observed significant upregulation in PD-L1 expression and signatures for interferon signaling, macrophages, T cells, and immune cell proliferation in samples harboring PD-L1 or PD-L2 SVs. Retrospective review of 12 studies that identified patients with SVs in PD-L1 or PD-L2 revealed > 50% (52/71) response rate to PD-1 immunotherapy with durable responses. CONCLUSION Our findings show that the 3′-UTR is frequently affected, and that SVs are associated with increased expression of ligands and immune signatures. Retrospective evidence from curated studies suggests this genomic alteration could help identify candidates for PD-1/PD-L1 immunotherapy. We expect these findings will better define PD-L1 and PD-L2 SVs in cancer and lend support for prospective clinical trials to target these alterations." @default.
• W4313892883 created "2023-01-10" @default.
• W4313892883 creator A5003346438 @default.
• W4313892883 creator A5006408243 @default.
• W4313892883 creator A5012759462 @default.
• W4313892883 creator A5014154182 @default.
• W4313892883 creator A5014491865 @default.
• W4313892883 creator A5019007552 @default.
• W4313892883 creator A5020142114 @default.
• W4313892883 creator A5020251022 @default.
• W4313892883 creator A5032382717 @default.
• W4313892883 creator A5034444686 @default.
• W4313892883 creator A5035593086 @default.
• W4313892883 creator A5036784999 @default.
• W4313892883 creator A5036926722 @default.
• W4313892883 creator A5047976994 @default.
• W4313892883 creator A5048499133 @default.
• W4313892883 creator A5053326285 @default.
• W4313892883 creator A5053671455 @default.
• W4313892883 creator A5059468437 @default.
• W4313892883 creator A5060466454 @default.
• W4313892883 creator A5080927178 @default.
• W4313892883 creator A5081272862 @default.
• W4313892883 creator A5084341181 @default.
• W4313892883 creator A5084523168 @default.
• W4313892883 creator A5085209621 @default.
• W4313892883 creator A5088856020 @default.
• W4313892883 creator A5091857373 @default.
• W4313892883 date "2023-01-01" @default.
• W4313892883 modified "2023-10-18" @default.
• W4313892883 title "Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations" @default.
• W4313892883 cites W1893566975 @default.
• W4313892883 cites W1985987855 @default.
• W4313892883 cites W1986354050 @default.
• W4313892883 cites W1991235944 @default.
• W4313892883 cites W2011228017 @default.
• W4313892883 cites W2114843025 @default.
• W4313892883 cites W2121906867 @default.
• W4313892883 cites W2125616358 @default.
• W4313892883 cites W2163401417 @default.
• W4313892883 cites W2230320310 @default.
• W4313892883 cites W2287768841 @default.
• W4313892883 cites W2321985702 @default.
• W4313892883 cites W2407603036 @default.
• W4313892883 cites W2412725897 @default.
• W4313892883 cites W2416748499 @default.
• W4313892883 cites W2609973112 @default.
• W4313892883 cites W2612431515 @default.
• W4313892883 cites W2626371219 @default.
• W4313892883 cites W2760942750 @default.
• W4313892883 cites W2765689414 @default.
• W4313892883 cites W2790823295 @default.
• W4313892883 cites W2796292093 @default.
• W4313892883 cites W2808442545 @default.
• W4313892883 cites W2892597528 @default.
• W4313892883 cites W2899927300 @default.
• W4313892883 cites W2903785716 @default.
• W4313892883 cites W2904076497 @default.
• W4313892883 cites W2904444972 @default.
• W4313892883 cites W2907554401 @default.
• W4313892883 cites W2909334052 @default.
• W4313892883 cites W2923864116 @default.
• W4313892883 cites W2960815591 @default.
• W4313892883 cites W2979952645 @default.
• W4313892883 cites W2980759299 @default.
• W4313892883 cites W2981790403 @default.
• W4313892883 cites W2982130750 @default.
• W4313892883 cites W2984395743 @default.
• W4313892883 cites W3004888802 @default.
• W4313892883 cites W3032793475 @default.
• W4313892883 cites W3047173611 @default.
• W4313892883 cites W3087519478 @default.
• W4313892883 cites W3118238647 @default.
• W4313892883 cites W3121483765 @default.
• W4313892883 cites W3127073653 @default.
• W4313892883 cites W3137624933 @default.
• W4313892883 cites W3150635270 @default.
• W4313892883 cites W3154805493 @default.
• W4313892883 cites W3156414413 @default.
• W4313892883 cites W3161537813 @default.
• W4313892883 cites W3172689903 @default.
• W4313892883 cites W3173096232 @default.
• W4313892883 cites W3180882235 @default.
• W4313892883 cites W3217354986 @default.
• W4313892883 cites W94592798 @default.
• W4313892883 doi "https://doi.org/10.1200/po.22.00300" @default.
• W4313892883 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36623238" @default.
• W4313892883 hasPublicationYear "2023" @default.
• W4313892883 type Work @default.
• W4313892883 citedByCount "0" @default.
• W4313892883 crossrefType "journal-article" @default.
• W4313892883 hasAuthorship W4313892883A5003346438 @default.
• W4313892883 hasAuthorship W4313892883A5006408243 @default.
• W4313892883 hasAuthorship W4313892883A5012759462 @default.
• W4313892883 hasAuthorship W4313892883A5014154182 @default.
• W4313892883 hasAuthorship W4313892883A5014491865 @default.
• W4313892883 hasAuthorship W4313892883A5019007552 @default.
• W4313892883 hasAuthorship W4313892883A5020142114 @default.
• W4313892883 hasAuthorship W4313892883A5020251022 @default.
• W4313892883 hasAuthorship W4313892883A5032382717 @default.

• next